Sarah Cannon Research Institute

Integrating ctDNA-Based ESR1 m Monitoring Into First-Line Care for ER+, HER2– Advanced Breast Cancer: A Consensus Workflow

Circulating tumor DNA (ctDNA) is an emerging tool in precision oncology that enables noninvasive tumor profiling, detection of minimal residual disease, and treatment monitoring. Furthermore, routine ctDNA analyses offer the potential to support more personalized and dynamic canc...

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Abstract Werner syndrome helicase (WRN) is a synthetic lethal target for microsatellite instability (MSI) cancers. In part 1 of this ongoing first-in-human, phase 1 trial, escalating doses of RO7589831 (VVD-133214), a first-in-class, WRN covalent inhibitor, were evaluated in 88 p...